Di Francia R, Rinaldi L, Cillo M, Varriale E, Facchini G, D'Aniello C, Marotta G, Berretta M
Department of Hematology, National Cancer Institute, Fondazione "G. Pascale" IRCCS, Naples, Italy.
Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5155-5163.
It is well-known that 75% of risk factors of chronic liver disease (CLD) are related to nutrition. These circumstances potentially progress towards liver steatosis, fibrosis and hepatocellular carcinoma (HCC). It still represents an enormous problem for the economy of public health worldwide. Furthermore, validated prevention programs could be the solution. Recent knowledge in understanding molecular determinants of energy liver metabolism and new genetic markers offers new insights into the pathogenesis of CLD and HCC. The main rationale of the present issue is to provide a summary of recent insights into the inherited variants regulating lipid metabolism (steatohepatitis) and acquired mutation for early diagnosis of HCC, specifically focusing on the significance of antioxidant agents and genotyping tests as a cost-effectiveness tool for the prevention of liver disease. Several national healthy programs worldwide promote the daily use of antioxidant nutrients either for the prevention and/or as complementary and alternative medicines (CAM). This review could be advising for the planning of a large-scale clinical trial including a combination strategy of antioxidant agents and genotyping tests in patients with high risk of CLD.
众所周知,慢性肝病(CLD)75%的风险因素与营养有关。这些情况可能会发展为肝脂肪变性、肝纤维化和肝细胞癌(HCC)。这对全球公共卫生经济来说仍是一个巨大问题。此外,经过验证的预防方案可能是解决办法。近期在理解肝脏能量代谢的分子决定因素和新的基因标志物方面的知识,为CLD和HCC的发病机制提供了新的见解。本期的主要目的是总结近期对调节脂质代谢(脂肪性肝炎)的遗传变异以及HCC早期诊断的获得性突变的见解,特别关注抗氧化剂和基因分型检测作为预防肝病的成本效益工具的重要性。全球有几个国家的健康计划提倡日常使用抗氧化营养素用于预防和/或作为补充和替代医学(CAM)。这篇综述可为规划一项大规模临床试验提供参考,该试验包括在CLD高危患者中采用抗氧化剂和基因分型检测的联合策略。